Skip to main content
BRIUMVI 150 mg/6mL injection, solution, concentrate by TG Therapeutics, Inc.
BRIUMVI, 150 mg/6mL, injection, solution, concentrate Drug class: CD20-directed Cytolytic Antibody. Available on prescription only. Listed by TG Therapeutics, Inc..
Prescription only

BRIUMVI

ublituximab

Listed by TG Therapeutics, Inc.

Strength
150 mg/6mL
Form
Injection, Solution, Concentrate
Route
Intravenous
Class
CD20-directed Cytolytic Antibody

What it contains

  • Ublituximab 150 mg/6mL

FDA record

Dosage form Injection, Solution, Concentrate
Route Intravenous
Drug class CD20-directed Cytolytic Antibody
Approval route BLA — biologic licence
NDC code 73150-150
FDA application BLA761238
RxNorm concept 2626353
Package sizes listed 1
Marketed since December 2022

Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.